Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
Clin. transl. oncol. (Print)
; 25(11): 3139-3151, 11 nov. 2023. tab, ilus
Article
in En
| IBECS
| ID: ibc-226839
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in clinical trials. For LC with Epidermal Growth Factor Receptor (EGFR) mutations, there is no clear association of this mutation with age. Geriatric assessments (GAs) and a multidisciplinary approach are essential for defining the optimal treatment. In this consensus, a group of experts selected from the Oncogeriatrics Section of the Spanish Society of Medical Oncology (Sección de Oncogeriatría de la Sociedad Española de Oncología MédicaSEOM), the Spanish Lung Cancer Group (Grupo Español de Cáncer de PulmónGECP) and the Association for Research on Lung Cancer in Women (Asociación para la Investigación del Cáncer de Pulmón en MujeresICAPEM) evaluate the scientific evidence currently available and propose a series of recommendations to optimize the management of older adult patients with advanced LC with EGFR mutations (AU)
Key words
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2023
Type:
Article